Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy ...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Petco Health & Wellness Co Inc (Symbol: WOOF), where a total of 26,358 contracts have ...

Citius Pharmaceuticals Inc (NASDAQ:CTXR) is a small-cap stock with a market capitalization of USD $26.49M. While investors primarily focus on the growth potential and competitive landscape of the ...

Citius Pharmaceuticals, Inc. CTXR announced that it has acquired the exclusive in-license rights of Dr. Reddy’s Laboratories RDY for E7777 (denileukin diftitox). The candidate is an improved ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

CTXR is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of CTXR shares has decreased $0.02 since the market last closed. This is a 3.10% ...